spacer
home > ebr > winter 2018 > keeping it clean
PUBLICATIONS
European Biopharmaceutical Review

Keeping It Clean

Advanced therapy medicinal products (ATMPs) are for human use, often in the field of regenerative medicine. They can be stratified into one of the following three categories of product: gene therapy; somatic cell therapy; and tissue engineering and regenerative medicine.

Figures 1 and 2 provide an overview of the distribution of ATMPs currently in development or on the market according to clinical application (1). The sponsors of ATMPs differ widely from the classical, heavily regulated, pharmaceutical market (see Figure 3). Currently, roughly 75% of ATMPs are being developed within the non-commercial sector (universities, hospitals, institutes and so forth) – an aspect that adds unique and significant regulatory challenges when guaranteeing that such products comply with the strict requirements for biological medicinal products.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Andy Bailey is a virologist who has been actively involved in the pathogen safety of biopharmaceuticals for over 20 years. Originally a biochemist, Andy served for nine years at the MRC virology unit in Glasgow, Scotland. In 1995, he moved as Director of virus validation services to Q-One Biotech, and later to the pathogen safety group of Baxter Healthcare in Vienna, Austria. Since 2005, Andy has been a founder and Chief Executive Officer of ViruSure in Vienna, Austria, a company specialising in virus and prion safety testing of biopharmaceutical products. Over the last 22 years, Andy has presented at numerous regulatory agencies, either in support of products or as an invited speaker at expert workshops.
spacer
Andy Bailey
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Countdown to the UK’s leading production line event begins

In light of Nick Peters’, author of the Annual Manufacturing report 2018, comment that “UK manufacturing has come a long way in recent years, as we have seen from their stellar performance in 2017,” it’s no surprise that the PPMA Show is gearing up for its biggest show to date when it returns to the NEC, Birmingham, between 25-27 September 2018.
More info >>

White Papers

The Role of the CRO in Effective Risk-Based Monitoring

Medpace

The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.
More info >>

 
Industry Events

4th Annual Formulation & Drug Delivery Congress

8-9 May 2018, London, UK

Oxford Global are proud to present our hugely popular 4th Annual Formulation & Drug Delivery Congress, 8th – 9th May 2018, London, UK.Over 300 delegates representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions will gather for over 40 presentations and case studies focused on the key issues in large molecule and small molecule drug formulation and drug delivery.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement